Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center

Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells

The goal of this clinical study is to learn more about the long-term safety, effectiveness and prolonged action of Kite study drugs, axicabtagene ciloleucel, brexucabtagene autoleucel, KITE-363, KITE-753, KITE-197, and anitocabtagene autoleucel in participants of Kite-sponsored interventional studies.
Hematologic, Leukemia, Lymphoma, Pediatric Leukemia, Pediatric Lymphoma
N/A
Both
Not Available
Not Available
Kassim, Adetola
International
Vanderbilt University
07-08-2022
Treatment
VICCCTT2170
NCT05041309

Eligibility

Not Available
ALL
false
Inclusion Criteria:

The individual must have received an infusion of gene-modified cells in a completed Kite-sponsored parent study, has not withdrawn full consent, and has discontinued or completed the post-treatment follow-up period in the parent study, as applicable

The individual must have received an infusion of gene-modified cells in a completed Kite-sponsored parent study, has not withdrawn full consent, and has discontinued or completed the post-treatment follow-up period in the parent study, as applicable

The individual must understand and voluntarily sign an Informed Consent Form (ICF) or an Informed Assent Form prior to any study-related assessments or procedures being conducted

The individual must understand and voluntarily sign an Informed Consent Form (ICF) or an Informed Assent Form prior to any study-related assessments or procedures being conducted

In the investigator's judgment, the individual is willing and able to complete the protocol-required follow-up schedule and comply with the study requirements for participation

In the investigator's judgment, the individual is willing and able to complete the protocol-required follow-up schedule and comply with the study requirements for participation



Exclusion Criteria:

Exclusion Criteria: none

Exclusion Criteria: none

To learn more about any of our clinical
trials, call 615-936-8422.